Ignite Creation Date:
2024-05-05 @ 4:34 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00260923
Status:
COMPLETED
Last Update Posted:
2011-11-08
First Post:
2005-11-30
Brief Title:
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Parallel-group Multicenter Study Comparing an Eight-week Treatment of Aliskiren 75 mg 150 mg and 300 mg to Placebo in Patients With Essential Hypertension
Status:
COMPLETED
Status Verified Date:
2011-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study for people diagnosed with hypertension to compare 3 doses 75 mg 150 mg and 300 mg of an experimental product aliskiren in comparison to a placebo Each patient is in the study for 8 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None